Notes to SEFA
All federal grant activities of Versiti, Inc. (Versiti) are included in the scope of the Uniform Grant Guidance. The Single Audit was performed in accordance with the provisions of the Uniform Grant Guidance. The Department of Health and Human Services (HHS) has been designated as Versiti’s oversight agency. Versiti utilizes approved indirect cost rates and does not elect to use the 15% de minimis cost rate as covered in 2 CFR 200.414, Indirect (F&A) costs.
The accompanying schedule of expenditures of federal awards is presented on the accrual basis of accounting. Grant revenue is recorded for financial reporting purposes when Versiti has met the qualifications for the respective grants.
There are no audits currently in process by other organizations of Versiti’s federal grant programs for the year ended December 31, 2025.
All federal awards are subject to review and audit by grantor agencies. Such audits could lead to requests for reimbursement by the grantor agencies for costs disallowed under the terms of the awards. It is the opinion of management that all costs charged against federal awards are allowable under the regulations of those programs.
Wisconsin operates a hemophilia treatment center, the Comprehensive Center for Bleeding Disorders (CCBD), under a federal grant sub-award from the Health Resources and Services Administration - Federal Assistance Listing Number #93.110. The grant sub-award, passed through from Great Lakes Hemophilia Foundation, Inc., allows Versiti to participate in the 340b Drug Pricing Program (Program), a federal program administered by the U.S. Department of Health and Human Services. During the year ended December 31, 2025, Wisconsin earned Program-related revenue (Program Income) of approximately $54,025,000. Program Income generated under the grant is restricted in accordance with the terms and conditions of the grant and the use of such funds is limited to patient care, education and supportive services necessary to provide comprehensive care to CCBD patients. During the year ended December 31, 2025, Wisconsin expended approximately $47,544,000 on expenses related to the sale of pharmaceutical product and uses of residual Program Income for operations of CCBD that comply with the restrictions on Program Income in accordance with the grant agreement. As of December 31, 2025, Wisconsin maintains approximately $46,205,000 of cumulative Program Income in investments on the consolidated statements of financial position that is restricted, as described above.